CTOs on the Move

Meta Materials

www.metamaterial.com

 
Meta Materials Inc. (META®), is an advanced materials and nanotechnology company. It develops new products and technologies using innovative sustainable science. Advanced materials can improve everyday products that surround us, making them smarter and more sustainable. META`s technology platforms enable global brands to develop new products to improve performance for customers in aerospace and defense, consumer electronics, 5G communications, batteries, authentication, automotive and clean energy.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
George Francis
Chief Information Officer Profile
Jonathan Waldern
Chief Technology Officer Profile

Similar Companies

Novagen

Novagen is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Highmark Delaware

Highmark Delaware is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Axial Therapeutics

We are harnessing the #gut brain axis & the #CNS to develop a new class of therapeutics for people with neurological diseases & disorders

Lumos Pharma

Lumos Pharma, based in Austin, Texas, is an early stage biotechnology company created to develop and commercialize a novel treatment for the rare disease Creatine Transporter Deficiency. Lumos Pharma is the exclusive licensee of technology and discoveries made in laboratories at the University of Cincinnati and has partnered with Key Opinion Leaders in the field and the United States National Institutes of Health to ensure success in developing a treatment for Creatine Transporter Deficiency.

Seres Health

Seres Health is a clinical-stage therapeutics company focused on discovering and developing Ecobiotic® therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome.  Founded by the Flagship Ventures innovation foundry, VentureLabs, Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span infectious, metabolic, and inflammatory diseases. Seres recently announced a research alliance with Mayo Clinic and has received over $20 million in funding to date.